Paper - WANFANG MED ONLINE

You Position: Home > Paper

Cardiotoxicity associated with antineoplastic drugs in breast cancer

( views:514, downloads:472 )

Author:: No author available

Journal Title:: CANCER RESEARCH AND CLINIC

Issue:: 2

DOI:: 10.3760/cma.j.issn.1006-9801.2011.02.002

Key Word:: 乳腺肿瘤;抗肿瘤联合化疗方案;蒽环类药物;曲妥珠单抗;心脏毒性;Breast neoplasms;Antineoplastic combined chemotherapy protocols;Anthracyclines;Trastuzumab;Cardiotoxicity

Abstract： Cardiotoxicity associated with anthracyclines and trastuzumab is discussed from clinical manifestations, pathogenesis, risk factors, monitoring methods, prevention and treatment.

Reference

[1]D B, Sawyer,R, Fukazawa,M A, Arstall,etc.Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane.[J].1999,84.
[2]Tripathy D,Lieberman G,Shak S,etc.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.[J].1999,17(9).
[3]Twelves C,O'Shaughnessy J,Aapro M.Treatment for anthracycline-pretreated metastatic breast cancer.[J].2002,7(Suppl.6).
[4]G, Bonadonna,L, Gianni,A, Santoro,etc.Drugs ten years later: epirubicin.[J].1993,4.
[5]G N, Hortobagyi,D, Frye,A U, Buzdar,etc.Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.[J].1989,63(1).
[6]Skovsgaard T,Nielsen SL,Jensen BV.Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.[J].2002,13(5).
[7]Orlandini C,Conte PF,Del Tacca-M,etc.Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors.[J].1999,17(11).
[8]Hudis Clifford,Pierri MaryKathryn,Keefe Deborah,etc.Cardiac dysfunction in the trastuzumab clinical trials experience.[J].2002,20(5).
[9]Hooning MJ,Botma A,Aleman BM,etc.Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.[J].2007,99(5).
[10]Lipshultz SE,Lipsitz SR,Mone SM,etc.Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.[J].1995,332(26).
[11]F M, Torti,M R, Bristow,A E, Howes,etc.Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.[J].1983,99.
[12]M E, Billingham,M R, Bristow,E, Glatstein,etc.Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation.[J].1977,1(1).
[13]Romond EH,Perez EA,Bryant J,etc.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.[J].2005,353(16).
[14]L, Gianni,E, Munzone,G, Capri,etc.Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.[J].1995,13.
[15]Martin FJ,Gabizon AA,Shapiro CL,etc.Cardiac safety of liposomal anthracyclines.[J].2004,31(6 Suppl.13).
[16]Rayson D,Vincent M,Chang J,etc.The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.[J].2008,107(3).
[17]Pluzanska A,Lee LW,Juozaityte E,etc.Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.[J].2004,15(10).
[18]Hirsch GA,Joseph J,Han Z,etc.Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase.[J].2003,8(2).
[19]Kalivendi S,Konorev EA,Kalyanaraman B,etc.Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways.[J].2004,279(24).
[20]Piras A,Cadeddu C,Massa E,etc.Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.[J].2007,12(9).
[21]Romestaing P,Namer M,Bonneterre J,etc.Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.[J].2006,17(1).
[22]Amadori D,Sledge G,Martin M,etc.Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.[J].2001,12(8).
[23]Gutheil J,Guthrie T,Khojasteh A,etc.Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.[J].2001,19(5).
[24]C, Praga,G, Beretta,P L, Vigo,etc.Adriamycin cardiotoxicity: a survey of 1273 patients.[J].1979,63(5).
[25]D D, Von Hoff,M W, Layard,P, Basa,etc.Risk factors for doxorubicin-induced congestive heart failure.[J].1979,91.
[26]Slamon DJ,Leyland-Jones B,Shak S,etc.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.[J].2001,344(11).
[27]O'Brien ME,Ackland SP,Alland L,etc.Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX(TM)/Doxil((R))) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.[J].2004,15(3).
[28]Hequet O,Espinouse D,Antal D,etc.Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.[J].2004,22(10).
[29]S S, Legha,R S, Benjamin,B, Mackay,etc.Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.[J].1982,96.
[30]J, Gehl,M, Boesgaard,T, Paaske,etc.Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic.[J].1996,7(7).